Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy |
| |
Authors: | Carsten Denkert Silvia Darb-Esfahani Sibylle Loibl Ioannis Anagnostopoulos Korinna J?hrens |
| |
Institution: | (1) Institute of Pathology, Charit?-Universit?tsmedizin Berlin, 10117 Berlin, Germany;(2) German Breast Group, Neu-Isenburg, Germany;(3) Institute of Pathology, Charit? Hospital, Campus Mitte, Schumannstr. 20/21, 10117 Berlin, Germany |
| |
Abstract: | Several studies suggest that the progression of malignant tumors as well as the response to chemotherapy and targeted therapy
is critically dependent on the immunological parameters that are derived from the host immune system as well as a modulation
of the immune system by therapeutic antibodies. It has been shown for many tumor types that the presence of a lymphocytic
infiltrate in different types of cancers is a positive factor for clinical outcome and that the response to neoadjuvant chemotherapy
is increased in a tumor with a prominent pretherapeutic infiltrate. Furthermore, new targeted therapies in breast cancer,
such as trastuzumab, as well as in hematological malignancies, such as rituximab and alemtuzumab, have been shown to interact
with immunological pathways, and this interaction is critical for response and clinical outcome. In neoplasms of lymphoid
and hematopoietic tissues, targeted therapies not only reduce toxic effects on normal tissues but also lead to modulations
of the immune system depending on the target molecule, its physiological function and cellular distribution. This review gives
an overview on clinical data on response to classical chemotherapy as well as molecular targeted therapy and its interaction
with the immune system. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|